Adding Capivasertib to Fulvestrant Results in Longer PFS in Patients with HR-positive, HER2-negative ABC Whose Disease Had Progressed to Previous AI With or Without a CDK4/6 Inhibitor
Findings from the CAPItello-291 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
EMA Recommends Granting a Marketing Authorisation for Piflufolastat (18F)
The benefit of this diagnostic radiopharmaceutical is its potential to diagnose prostate cancer during primary staging of patients at high risk and in the staging of patients with a suspected recurrence
Olaparib Plus Bevacizumab Provides Clinically Meaningful OS Improvement for Newly Diagnosed Patients with Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
Findings from the prespecified final overall survival analysis of the PAOLA-1/ENGOT-ov25 study
FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma
Evidence for efficacy is based on the results from the EPCORE NHL-1 study
Significant PFS Benefit in Patients with HR-positive, HER2-negative MBC Who Switched Endocrine Treatment and Received Ribociclib After Previous CDK4/6 Inhibitor and Different Endocrine Therapy
Findings from the MAINTAIN study
Use of Immune Checkpoint Inhibitors is Safe and Effective in Patients with Cancer and HIV Even in Those on Antiretroviral Therapy
Findings from the CATCH-IT Consortium study
Pralsetinib: Measures to Minimise Increased Risk for Tuberculosis
Before starting treatment with pralsetinib, patients should be evaluated for active and latent tuberculosis
Patient-Reported Outcomes Support the Overall Benefit of Trastuzumab Deruxtecan for Patients with HER2-positive Metastatic Breast Cancer
PRO data from the DESTINY-Breast03 study
ctDNA Sequencing Reliably Detects KIT/PDGFRA Mutations and Correlates with Outcomes in Patients with Metastatic, TKI-Resistant GIST Treated with Avapritinib or Regorafenib
Findings from the ctDNA analysis in the VOYAGER study
Venetoclax-Obinutuzumab With or Without Ibrutinib Is Superior to Chemoimmunotherapy in First-Line Treatment for Fit Patients with CLL
Findings from the GAIA–CLL13 study
Cabozantinib Plus Nivolumab and Ipilimumab Results in Longer PFS in Previously Untreated, Advanced RCC with Intermediate or Poor Prognostic Risk
Findings from the COSMIC-313 study
EMA Recommends Granting a Conditional Marketing Authorisation for Glofitamab
It is intended for the treatment of adult patients with relapsed or refractory DLBCL after two or more lines of systemic treatment